A Pilot Study of Low-Dose Zidovudine in Human Immunodeficiency Virus Infection
Open Access
- 11 October 1990
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 323 (15), 1015-1021
- https://doi.org/10.1056/nejm199010113231502
Abstract
Zidovudine delays the progression of human immunodeficiency virus (HIV) infection but is associated with hematologic toxicity at high doses. Regimens are needed that preserve or enhance efficacy and reduce toxicity. Acyclovir has been reported to potentiate the effect of zidovudine on HIV in vitro.This publication has 28 references indexed in Scilit:
- Zidovudine in Asymptomatic Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1990
- The Prognostic Value of Cellular and Serologic Markers in Infection with Human Immunodeficiency Virus Type 1New England Journal of Medicine, 1990
- The Risk ofPneumocystis cariniiPneumonia among Men Infected with Human Immunodeficiency Virus Type 1New England Journal of Medicine, 1990
- Plasma Viremia in Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1989
- Effect of zidovudine on serum human immunodeficiency virus core antigen levels. Results from a placebo-controlled trialArchives of Internal Medicine, 1988
- RESUMPTION OF HIV ANTIGEN PRODUCTION DURING CONTINUOUS ZIDOVUDINE TREATMENTThe Lancet, 1988
- Long-Term Evaluation of HIV Antigen and Antibodies to p24 and gp41 in Patients with HemophiliaNew England Journal of Medicine, 1987
- The Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987
- The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987
- Predictors of the Acquired Immunodeficiency Syndrome Developing in a Cohort of Seropositive Homosexual MenNew England Journal of Medicine, 1987